Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Immunotherapy. 2018 Mar;10(3):177–188. doi: 10.2217/imt-2017-0119

Figure 3.

Figure 3

Tumor appearance and scab formation 24 h after intralesional injection of therapeutic products. Tumor appearance of subcutaneous F9 teratocarcinoma (upper panel) and WEHI-164 fibrosarcoma (lower panel) 24 h after intralesional injection of PBS, F8-IL2, F8-TNF or the combination of F8-IL2 and F8-TNF.